GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action
Introduction
Glial cell line-derived neurotrophic factor (GDNF) was originally discovered as a potent neurotrophic factor with prominent survival-promoting and restorative effects for midbrain dopaminergic neurons in vitro and in animal models of Parkinson’s disease (PD; Lin et al., 1993, Tomac et al., 1995a, Unsicker et al., 1999, Airaksinen and Saarma, 2001, Krieglstein, 2004). This discovery, together with promising results obtained in primate models of PD (Gash et al., 1996), raised great expectations to develop GDNF into a potent drug to cure or ameliorate the pathological symptoms of PD. However, despite the positive outcome of small open-label clinical trials (Gill et al., 2003, Patel et al., 2005, Slevin et al., 2005), other studies including a recent double-blind placebo-controlled study failed to demonstrate efficacy and safety of GDNF (Kordower et al., 1999, Nutt et al., 2003, Lang et al., 2006, Sherer et al., 2006).
We have previously shown for several neuron populations that GDNF does not have neurotrophic activity on its own, but requires TGF-β to act as a neurotrophic factor (Krieglstein et al., 1998, Schober et al., 1999). On a molecular level, we have provided evidence that TGF-β is required to target the GDNF co-receptor α1 (GFRα1) to the cell surface (Peterziel et al., 2002). In addition, GDNF and TGF-β signaling seem to converge both at the PI3-K/Akt as well as ERK pathways. Cooperativity of GDNF and TGF-β is also important at the in vivo level.
Preganglionic sympathetic neurons in the spinal cord die following destruction of a major target, the adrenal medulla, but survive when supplemented with GDNF. We found that neutralization of endogenous TGF-β abolished this protective effect of GDNF (Schober et al., 1999). Together, these data suggest the hypothesis that GDNF may require TGF-β for mediating its neurotrophic effect also in the lesioned nigrostriatal system, possibly including human PD. Consistent with this notion, chromaffin cells, which co-store and co-release GDNF and TGF-β (Krieglstein et al., 1998), have been shown to exert restorative effects on the lesioned nigrostriatal system in animal models and human PD (Bohn et al., 1987, Goetz et al., 1991, Luquin et al., 1999, Espejo et al., 2001, Toledo-Aral et al., 2003).
We now report that neutralizing antibodies against TGF-βs applied together with GDNF to the MPTP-lesioned striatum abolish the neuroprotective effect of GDNF. Specifically, the GDNF-mediated protection of striatal dopamine (DA) levels, relative density of striatal tyrosine hydroxylase (TH)-ir fibers, and the number of TH-ir nigral neurons are significantly reduced or abolished by neutralizing endogenous TGF-β. TGF-β antibodies are not toxic and do not interfere with internalization and retrograde transport of iodinated GDNF from the striatum to the substantia nigra (SN). MPTP treatment causes a 3-fold increase in striatal TGF-β2 mRNA, consistent with the notion that members of the TGF-β family may be available and effective in this system. In summary, we conclude that trophic effects of GDNF in the MPTP-lesioned nigrostriatal DA system require endogenous TGF-β.
Section snippets
Animals
A total of 133 male adult (body weight: 20–25 g; 4–6 months old) C57Bl6 mice, 16 male adult (4–6 months old) Engrailed-1 heterozygous (En-1 +/−) mice (129J/C57Bl6), and 16 corresponding wildtype littermates were used for dopamine (DA) measurements, RT-PCR, quantitative histological analysis of striatum and substantia nigra (SN), and for retrograde transport studies (see Table 1).
MPTP administration
Mice received three intraperitoneal injections at 24 h intervals of MPTP
TGF-β antibodies abolish protection of DA levels by GDNF in the MPTP lesioned striatum
It has previously been shown that GDNF exerts both protective and reparative actions in the MPTP-lesioned nigrostriatal DA system (Tomac et al., 1995a, Gash et al., 1996, Cheng et al., 1998). We have reported that the neurotrophic and protective effects of GDNF are crucially dependent on the simultaneous presence of TGF-β, both in neuronal cell cultures and in an in vivo lesion model of the peripheral nervous system (Krieglstein et al., 1998, Schober et al., 1999). To begin to explore whether
Discussion
The present study provides evidence that TGF-β acts as an essential co-factor of GDNF in a classic model of PD, the MPTP-lesioned mouse (Dauer and Przedborski, 2003, Schober, 2004). The evidence is based on the neutralization of endogenous TGF-β using a monoclonal antibody that recognizes all three TGF-β isoforms and is highly specific for TGF-β (Krieglstein et al., 2000).
Acknowledgments
We thank Richard Hertel, Jutta Fey, Martina Scharpff and Angelika Brüntgens for valuable technical assistance, and Daniel Gherbassi for providing engrailed heterozygous mice (En-1 +/−). Supported by the German Research Foundation (through DFG-Forschungszentrum CMPB (to KK); DFG SFB 636 TP A5 (to KU); NIH grant EY 12841 (to CSvB).
References (74)
- et al.
Transforming growth factor beta2 haploinsufficient mice develop age-related nigrostriatal dopamine deficits
Neurobiol. Dis.
(2006) - et al.
The GDNF family ligands and receptors—Implications for neural development
Curr. Opin. Neurobiol.
(2000) - et al.
Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain
J. Chem. Neuroanat.
(2001) - et al.
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice
Neurosci. Lett.
(1998) - et al.
Retrograde propagation of GDNF-mediated signals in sympathetic neurons
Mol. Cell. Neurosci.
(2004) - et al.
Parkinson's disease: mechanisms and models
Neuron
(2003) - et al.
Application of a blood–brain barrier-penetrating form of GDNF in a mouse model for Parkinson's disease
Brain Res.
(2006) - et al.
Transforming growth factor-betas in neurodegenerative disease
Prog. Neurobiol.
(1998) - et al.
Transforming growth factor-beta promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridium ion toxicity
Neuroscience
(1994) - et al.
Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen
Neuron
(1999)
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease
Neurosci. Lett.
Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains
Neurosci. Lett.
Suppressor and oncogenic roles of transforming growth factor-beta and its signalling pathways in tumor genesis
Adv. Cancer Res.
TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic nerons
Neuron
Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections
Neuroscience
Interhemispheric nigrostriatal projections in the rat: bifurcating nigral projections and loci of crossing in the diencephalon
Brain Res. Bull.
TGF-beta promotes survival of mesencephalic dopaminergic neurons in cooperation with SHH and FGF-8
Neurobiol. Dis.
Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice
Neurobiol. Dis.
Transforming growth factor β1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice
Mol. Cell. Neurosci.
Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment
Neuroscience
Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system
Neuroscience
TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
Exp. Neurol.
The GDNF family: signalling, biological functions and therapeutic value
Nat. Rev. Neurosci.
Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta
J. Neurosci.
Parkinson disease gene therapy moves towards the clinic
Nat. Med.
TGF-beta rescues target-deprived preganglionic sympathetic neurons in the spinal cord
Eur. J. Neurosci.
Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers
Science
Location and size of dopaminergic and serotonergic cell populations are controlled by the position of the midbrain–hindbrain organizer
J. Neurosci.
Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture
J. Neurochem.
Neuropathological changes caused by hydrocephalus
Acta Neuropathol.
Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ
J. Neurosci.
Transforming growth factor-beta(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo
J. Neurosci.
Receptor-mediated transport in CNS neurons after intraventricular administration of NGF and other growth factors
J. Comp. Neurol.
Immunohistochemical localization of transforming growth factor-βs in the nervous system of the mouse embryo
Development
Functional recovery in parkinsonian monkeys treated with GDNF
Nature
Crossed connections of the substantia nigra in the rat
J. Comp. Neurol.
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease
Nat. Med.
Cited by (73)
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
2022, Pharmacology and TherapeuticsCitation Excerpt :This effect is mediated by mGluR3, as LY379268 enhanced GDNF production in mGluR2 knockout mice but failed to enhance GDNF levels in mGluR3 knockout mice (Battaglia et al., 2009). Furthermore, the protective effect of GDNF against MPTP-induced toxicity is dependent on TGF-β, whose production also appears to be regulated by mGluR3 rather than mGluR2 (Corti et al., 2007; Schober et al., 2007). However, in marmosets with MPTP-induced lesion, treatment with mGluR2/3 dual agonist LY354740 and mGluR2-specific PAM LY487379 reduced L-DOPA-induced dyskinesia and psychosis-like behaviour (Frouni et al., 2019; Nuara, Gourdon, & Huot, 2022; Sid-Otmane et al., 2020).
The promise of the TGF-β superfamily as a therapeutic target for Parkinson's disease
2022, Neurobiology of DiseaseTransforming growth factor-β1 acts via TβR-I on microglia to protect against MPP<sup>+</sup>-induced dopaminergic neuronal loss
2016, Brain, Behavior, and ImmunityDynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease
2014, Neurobiology of DiseaseCitation Excerpt :In humans, a positive association between genetic variations in the TGF-β gene and PD has been suggested, while mice deficient for TGF-β displayed a reduced neuronal loss in the SNc (Andrews et al., 2006; Goris et al., 2007). Furthermore, TGF-β co-infusion synergized with glial cell-derived neurotrophic factor (GDNF) beneficial effects in PD models (Gonzalez-Aparicio et al., 2010; Schober et al., 2007). Infusion of IL-10 protected against lipopolysaccharide (LPS)-induced cell death of dopaminergic neurons (Krieglstein et al., 1995).
TGFβ3, dibutyryl cAMP and a notch inhibitor modulate phenotype late in stem cell-derived dopaminergic neuron maturation
2023, Frontiers in Cell and Developmental Biology